Long-term outcome of autologous stem cell transplantation in light chain deposition disease

被引:79
|
作者
Lorenz, Elizabeth C. [1 ]
Gertz, Morie A. [1 ]
Fervenza, Fernando C. [1 ]
Dispenzieri, Angela [1 ]
Lacy, Martha Q. [1 ]
Hayman, Suzanne R. [1 ]
Gastineau, Dennis A. [1 ]
Leung, Nelson [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
关键词
light chain deposition disease; monoclonal gammopathy; paraproteinemia; renal dysfunction; stem cell transplantation;
D O I
10.1093/ndt/gfm918
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Light chain deposition disease (LCDD) is a systemic disorder characterized by deposition of non-amyloid monoclonal light chains. Renal dysfunction is a ubiquitous manifestation of the LCDD disease. Reports suggest that high-dose chemotherapy and autologous stem cell transplantation (ASCT) may be beneficial in the treatment of LCDD. However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD. Methods. Six patients with LCDD have been transplanted at our institution since 2001. Patients received dexamethasone alone, dexamethasone plus thalidomide or no chemotherapy prior to conditioning. All the patients underwent high-dose melphalan conditioning after stem cell mobilization. Results. Three of the six patients had concurrent multiple myeloma (MM), and one patient was on haemodialysis prior to transplantation. Four patients were male and two were female. The median age was 43.5 years with a median serum creatinine of 2.4 mg/dl and a median estimated glomerular filtration rate (eGFR) of 26.5 ml/min/1.73 m(2). Five patients survived ASCT and one died on Day 26 of transplantation. Median follow-up was 31.7 months (range 31.3-60.7 months) after ASCT. Of the surviving patients, all the five achieved a haematological response post-transplantation although two ultimately relapsed and required further chemotherapy. The eGFR of one patient declined with relapse and improved with treatment, while the eGFR of the second patient remained stable throughout relapse and treatment. The patient on haemodialysis prior to transplantation continued to require it afterward, but ultimately received a renal transplant. Median reduction in proteinuria was 92% and median improvement in eGFR was 95%. Of the four evaluable patients all achieved criteria for a renal response after ASCT. Conclusions. ASCT may be an effective therapy for renal dysfunction associated with LCDD. In cases where kidney dysfunction persists after ASCT, a haematological response may permit successful kidney transplantation with improved graft viability and decreased risk of recurrence.
引用
收藏
页码:2052 / 2057
页数:6
相关论文
共 50 条
  • [1] Long-term renal outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz, EC
    Gertz, MA
    Fervenza, FC
    Leung, N
    BLOOD, 2005, 106 (11) : 468B - 468B
  • [2] Long-term outcome of renal transplantation in light-chain deposition disease
    Leung, N
    Lager, DJ
    Gertz, MA
    Wilson, K
    Kanakiriya, S
    Fervenza, FC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (01) : 147 - 153
  • [3] Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease
    Brioli, A.
    Zamagni, E.
    Pasquali, S.
    Tosi, P.
    Tacchetti, P.
    Perrone, G.
    Pantani, L.
    Petrucci, A.
    Zannetti, B. A.
    Baccarani, M.
    Cavo, M.
    BONE MARROW TRANSPLANTATION, 2012, 47 (09) : 1248 - 1249
  • [4] Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease
    A Brioli
    E Zamagni
    S Pasquali
    P Tosi
    P Tacchetti
    G Perrone
    L Pantani
    A Petrucci
    B A Zannetti
    M Baccarani
    M Cavo
    Bone Marrow Transplantation, 2012, 47 : 1248 - 1249
  • [5] Autologous Stem Cell Transplantation in the Treatment of Pulmonary Light Chain Deposition Disease
    Rendo, Matthew
    Franks, Teri J.
    Galvin, Jeffrey R.
    Berglund, Andrew
    Volk, Charles
    Peterson, Matthew
    CHEST, 2021, 160 (01) : E13 - E17
  • [6] Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation
    Gonzalez-Lopez, Tomas J.
    Vazquez, Lourdes
    Flores, Teresa
    San Miguel, Jesus Fernando
    Garcia-Sanz, Ramon
    CLINICS AND PRACTICE, 2011, 1 (04) : 205 - 208
  • [7] LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT
    Garderet, Laurent
    Gras, Luuk
    Koster, Linda
    Montserrat, Rovira
    Vincent, Laure
    Kobbe, Guido
    Pillai, Srinivas
    Deeren, Dries
    Kaufmann, Martin
    Kuball, Jurgen
    Ozdogu, Hakan
    Pascual Gascon, Maria Jesus
    Passweg, Jakob
    Rye, Adam
    Salmenniemi, Urpu
    Snowden, John
    Larsen, Thomas Stauffer
    Leleu, Xavier
    Gastaud, Lauris
    Sokolowska, Joanna Drozd
    Raj, Kavita
    Beksac, Meral
    Schonland, Stefan
    Hayden, Patrick
    Mclornan, Donal
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 478 - 478
  • [8] Autologous hematopoietic stem cell transplantation in acute myeloid leukaemia: Long-term outcome
    Sharif, Azizan
    Mui, Tan Sen
    Chuan, Ong Tee
    Kadir, Sharifah Shahnaz Syed Abdul
    Wah, Ho Kim
    Boon, Law Kian
    BONE MARROW TRANSPLANTATION, 2019, 54 : 376 - 376
  • [9] Long-term outcome after kidney transplantation with or without stem cell transplantation in immunoglobulin light chain (AL) amyloidosis
    Leung, N.
    Herrmann, S. M. S.
    Dispenzieri, A.
    Kumar, S.
    Lacy, M. Q.
    Russell, S. J.
    Buadi, F. K.
    Hayman, S. R.
    Zeldenrust, S. R.
    Dingli, D.
    Dean, P. G.
    Prieto, M.
    Nyberg, S.
    Stegall, M.
    Fervenza, F. C.
    Gertz, M. A.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 168 - 168
  • [10] Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT
    Garderet, Laurent
    Luuk, Gras, Sr.
    Koster, Linda
    Rovira, Montserrat
    Vincent, Laure
    Kobbe, Guido
    Pillai, Srinivas
    Deeren, Dries
    Kaufmann, Martin
    Kuball, Jurgen
    Ozdogu, Hakan
    Pascual, Maria Jesus
    Passweg, Jakob R.
    Rye, Adam
    Salmenniemi, Urpu
    Snowden, John
    Larsen, Thomas Stauffer
    Leleu, Xavier
    Gastaud, Lauris
    Drozd-Sokolowska, Joanna
    Raj, Kavita
    Beksac, Meral
    Schonland, Stefan
    Hayden, Patrick John
    McLornan, Donal P.
    BLOOD, 2023, 142